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Abstract
A degradable, poly (lactic-co-glycolic acid) (PLGA), 
gentamicin-loaded prophylactic coating for hydroxyapatite 
(HA)-coated cementless hip prostheses is developed with 
similar antibacterial efficacy as offered by gentamicin-
loaded cements for fixing traditional, cemented prostheses 
in bone. We describe the development pathway, from in 
vitro investigation of antibiotic release and antibacterial 
properties of this PLGA-gentamicin-HA-coating in 
different in vitro models to an evaluation of its efficacy 
in preventing implant-related infection in rabbits. 
Bone in-growth in the absence and presence of the 
coating was investigated in a canine model. The PLGA-
gentamicin-HA-coating showed high-burst release, 
with antibacterial efficacy in agar-assays completely 
disappearing after 4 days, minimising risk of inducing 
antibiotic resistance. Gentamicin-sensitive and gentamicin-
resistant staphylococci were killed by the antibiotic-loaded 
coating, in a simulated prosthesis-related interfacial gap. 
PLGA-gentamicin-HA-coatings prevented growth of 
bioluminescent staphylococci around a miniature-stem 
mounted in bacterially contaminated agar, as observed 
using bio-optical imaging. PLGA-gentamicin-HA-coated 
pins inserted in bacterially contaminated medullary canals 
in rabbits caused a statistically significant reduction in 
infection rates compared to HA-coated pins without 
gentamicin. Bone ingrowth to PLGA-gentamicin-HA-
coated pins, in condylar defects of Beagle dogs was not 
impaired by the presence of the degradable, gentamicin-
loaded coating. In conclusion, the PLGA-gentamicin-
HA-coating constitutes an effective strategy for infection 
prophylaxis in cementless prostheses.
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Total hip replacements have been performed since the early 
1960s on patients suffering from hip joint arthrosis. At 
present, total hip replacement has an incidence higher than 
150 procedures per 100,000 habitants in most industrialised 
countries, and accordingly about one million hips are 
replaced by prostheses worldwide every year (Web ref. 
1). On average, the incidence rate of this procedure has 
increased by 25 % between 2000 and 2009 and this trend 
is predicted to continue due to ageing populations and 
growing prevalence of obesity (Web ref. 1). Projection 
models claim that the incidence of total hip replacement 
is expected to increase at least until 2030 in the United 
States (Kurtz et al., 2014; Nemes et al., 2014), which 
is likely a worldwide valid prediction. From the onset, 
high infection rates have plagued patients and treating 
orthopaedic surgeons. Nevertheless, total hip replacement 
is, at the same time, amongst the clinically most successful 
procedures, providing almost immediate relief of pain and 
restoration of function. Along with the projected increase 
in incidence of total hip replacement, is an increase in the 
numbers of patients suffering from infection. Although 
infections rates may be considered low at around 1-2 % 
(Hamilton and Jamieson, 2008), the economical downside 
of infection makes 1-2 % unacceptably high, due to the 
enormous number of implant recipients (Kurtz et al., 2014). 
Moreover, many patients have a severely reduced quality 
of life after an episode of infection (Helwig et al., 2014).
 Despite the use of local and systemic antibiotic 
prophylaxis, strict hygiene protocols, and special sterile 
enclosures with laminar flow during surgery, the deep 
infection rate of primary hip replacements remains between 
1 % and 2 % (Hamilton and Jamieson, 2008). Based on 
past experiences (Knobben et al., 2006), it seems likely that 
improving hygiene and surgical discipline are insufficient 
countermeasures to prevent peri-operative contamination 
of implant surfaces. This is especially true for hip and 
knee replacements, often still requiring long incisions and 
surgical times of 1-2 h. When peri-operatively introduced 
bacteria are able to grow into a biofilm that protects the 
colonising organisms against the host immune system 
and antibiotics, the fate of the implant is a race for the 
surface between host tissue integration and bacterial 
colonisation (Gristina, 1987). This frequently results 
in surgical removal and subsequent replacement of the 
implant, at considerable costs (Vanhegan et al., 2012). 
In vitro (Subbiahdoss et al., 2010) as well as clinical 
evaluations (Deacon et al., 1996) have demonstrated that 
tissue integration provides protection against infection. 
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This is especially important for the long-term protection 
of an implant against post-operative spreading of bacteria 
disseminated from infections elsewhere in the body or 
entering the bloodstream after routine dental treatments 
(Walman et al., 1997).
 Polymethylmethacrylate bone cement has traditionally 
been used to bond prosthetic replacements into bone. 
The use of antibiotic-loaded bone cements has been 
demonstrated to yield a lower risk of both septic 
(Engesaeter et al., 2003; Wang et al., 2013) and aseptic, 
or possibly more accurately “presumed aseptic” loosening 
than unloaded cements (Parvizi et al., 2011) in primary 
prostheses as well as in revision surgery, despite 
administration of systemic antibiotic prophylaxis. In 
addition, local antibiotic delivery from bone cements has 
been proven to yield prophylactic effects against post-
operative infections both in experimental and clinical 
studies (Malchau et al., 2002; Tunney et al., 2007). The 
Norwegian Arthroplasty Register (containing a total of 
97,344 total hip replacements) indicated that there was 
a broad and consistent use of cemented prostheses over 
the period 1987-2007, representing about 85 % of all 
replacements (Dale et al., 2009). Register data also indicate 
a continuous increase in the use of antibiotic-loaded 
cements, from 45 % in the period 1987-1992 up to 99 % 
in the period 2003-2007 (Dale et al., 2009). Consequently, 
orthopaedic surgeons all over Europe now routinely use 
antibiotic-loaded bone cements in all cemented primary 
hip replacements and revision surgeries, and cemented 
fixation remains a common clinical solution.
 Lately, due to progressive improvements in prosthesis 
design and changes in prosthetic material, providing 
better osseointegration, cementless prostheses have 
experienced increasing popularity and growth in use 
especially in younger and more active patients. Important 
in the increasing popularity of cementless prostheses is 
the development of grit-blasted, porous or hydroxyapatite 
(HA) coatings to stimulate osseointegration. Grit-blasting 
is known to stimulate osseointegration, and coating of 
prostheses with calcium phosphate ceramics, such as HA 
(Oosterbos et al., 2004), further enhance bone bonding in a 
relatively short period of time (Geesink et al., 1987; Søballe 
et al., 1993) under load-bearing conditions (Søballe et al., 
1990). Clinically, osseointegration allowing full weight-
bearing occurs within 4 to 12 weeks (Markmiller et al., 
2011). As a result of these developments, currently in the 
United States, about 90 % of all femoral stems implanted 
use cementless procedures (Web ref. 2). However, as a 
result of the use of cementless prostheses, antibiotic-loaded 
bone cements will no longer be available for prophylaxis 
to reduce risks of peri-operative bacterial contamination. 
Presently, no effective strategies are clinically available 
for local antibiotic prophylaxis in the case of cementless 
prostheses. A recent report shows that while infection 
rates associated with total hip replacements are increasing 
in general, the increase is most marked in the case of 
cementless hip replacements (Dale et al., 2009).
 In vitro experiments indicated that gentamicin-
releasing coatings on grit-blasted titanium surfaces for 
use as cementless prostheses, with 1.0 mg gentamicin/
cm2 of the antibiotic sandwiched between the surface and 
a biodegradable overlayer, possess a similar antibacterial 
efficacy as clinically employed gentamicin-loaded bone 
cements (Neut et al., 2011). However, no such antibiotic-
releasing coating has been described for cementless HA-
coated prostheses.
 This study describes the development of a new, robust 
HA-coating containing gentamicin on titanium alloy (Ti-
6Al-4V) covered with a protective, biodegradable poly 
(lactic-co-glycolic acid) (PLGA)-overlayer, that prevents 
colonisation of cementless orthopaedic prostheses by peri-
operatively introduced bacteria. Initial in vitro experiments 
describe evaluation of the gentamicin release characteristics 
and antibacterial efficacies of the PLGA-gentamicin-HA-
coatings against a number of staphylococcal strains, among 
which two were gentamicin-resistant. Staphylococcal 
strains were used since staphylococci constitute the 
number one causative strain for orthopaedic implant 
infection (Zimmerli et al., 2004). Antibacterial efficacy 
was determined using traditional zone of inhibition 
measurements on agar plates, but also using models to 
analyse antibacterial efficacies in confined spaces and in a 
geometrically relevant set-up with miniature stems, using 
bio-optical imaging. In vivo evaluation of the antibacterial 
efficacy of the PLGA-gentamicin-HA-coating was carried 
out in a contaminated prosthesis model in rabbits, while 
effects of the coating on bone fixation and osseointegration 
were assessed in a canine condylar defect model, to 
demonstrate technology potential for clinical translation.
Materials and methods
PLGA-gentamicin-HA-coated titanium coupons, 
miniature stems, and pins
The Ti-6Al-4V surface was grit-blasted with alumina 
grit. Grit-blasting is used to roughen the surface to obtain 
better mechanical adhesion of the HA-coating. After 
cleaning ultrasonically in purified water and passivating, 
HA was spray-coated on the grit-blasted Ti-6Al-4V, 
according to DePuy’s standard specification for the 
clinically established Corail® total hip system (plasma 
sprayed HA with a thickness of 155 µm, as per the 
detailed specification described by Reignier et al. (2011)). 
Gentamicin sulphate (Lek Pharmaceuticals, Slovenia) was 
applied on HA-coated, grit-blasted Ti-6Al-4V coupons 
(diameter 2.5 cm; height 0.4 cm; surface area 4.9 cm2) 
using a proprietary spraying technique (Web ref. 3) and its 
surface concentration was adjusted to 1 mg/cm2 bioactive 
gentamicin. This concentration was chosen, because on 
grit-blasted Ti-6Al-4V surfaces, this gentamicin surface 
concentration yielded a similar antibacterial efficacy to that 
of gentamicin-loaded bone cement (Neut et al., 2011). The 
gentamicin surface concentration of 1 mg/cm2 is controlled 
through the process by spray time and the gentamicin 
content is checked by an HPLC method. Finally, a PLGA 
layer (PURAC® 5002, Purac Biochem, Gorinchem, The 
Netherlands) with a methyl ester as the terminal functional 
group was applied over the HA-containing gentamicin 
coating using an ultrasonic coating process. The PLGA 
used had an inherent viscosity of 0.2 (molecular weight 
of 17 kDa) and a 50:50 molar ratio of PLA: PGA. This 
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thin PLGA-overlayer serves as a biodegradable layer to 
protect the gentamicin layer during transit and surgical 
implantation and not a priori to control antibiotic release. It 
quickly degrades in vivo to ensure normal osseointegration.
 In addition, PLGA-gentamicin-HA-coated, grit-blasted 
Ti-6Al-4V miniature stems (diameter 1.2 cm and length 
10.0 cm) and pins (diameter of 0.25 cm, length of 4.5 cm for 
the infection prophylaxis model, and diameter of 0.5 cm, 
length of 1.5 cm for the bone ingrowth studies) with a 
protective PLGA-overlayer were made. Fig. 1 presents a 
schematic overview of the different coating layers.
 All coupons (HA- and PLGA-gentamicin-HA-coated), 
miniature stems, and pins were manufactured (DePuy 
Ireland, Cork, Ireland) under conditions employed for 
manufacturing implants and were supplied in individual 
25 kGy gamma-sterilised surgical packs.
Gentamicin release
In order to establish the longevity of the gentamicin 
release from the PLGA-gentamicin-HA-coating, coupons 
were immersed in 20 mL of sterile phosphate buffered 
saline (PBS; NaCl 8.76 g/L, K2HPO4 43.5 g/L, KH2PO4 
34.5 g/L, pH 7.4) and incubated at 37 °C, as described 
before in a study on gentamicin-coatings in absence of 
HA (Neut et al., 2011). At designated time intervals (1, 
6, 24, 30, 48, 72, 168 and 336 h), 500 µL aliquots of 
the gentamicin-PBS solution were removed and stored 
at 4 °C for subsequent determination of the gentamicin 
concentration. Gentamicin concentrations were determined 
by a fluorescence polarisation immuno-assay, having a 
sensitivity of 0.30 μg/mL and an assay sample range of 
0.44-13.80 μg/mL (AxSYM, Abbott Laboratories, USA). 
Samples with gentamicin concentrations reported as 
greater than 10.00 μg/mL were diluted.
Scanning electron microscopy (SEM)
The surfaces of the PLGA-gentamicin-HA-coated coupons 
before and after complete gentamicin release were 
investigated using SEM, as described before in a study on 
gentamicin-coatings in absence of HA (Neut et al., 2011). 
Examination was done at 2.0 kV in a JEOL field emission 
scanning electron microscope type 6301F. Coupons were 
sputter-coated with a 3 nm thick conductive layer of gold/
palladium (80/20).
Bacterial strains for in vitro studies
Six staphylococcal strains were used in the in vitro parts 
of this study, including two gentamicin-resistant strains, 
with minimal inhibitory concentration (MIC) > 4 μg/mL. 
S. aureus 5298 (MIC gentamicin = 0.2 µg/mL), S. aureus 
7323 (MIC gentamicin = 1.5 µg/mL), S. epidermidis 
7388 (MIC gentamicin > 256 µg/mL), and S. epidermidis 
7391 (MIC gentamicin = 24 µg/mL) were obtained from 
patients with infected joint arthroplasties and retrieved 
Fig. 1. Scanning electron micrographs of a PLGA-gentamicin-HA-coating prior to (left) and after gentamicin-release 
during 2 weeks in PBS (right), together with a schematic presentation of the built-up of the coating, including the 
protective PLGA-overlayer. The bar equals 100 µm for low magnification micrograph, and 10 µm for the insert.
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during revision surgery (Department of Orthopaedic 
Surgery at the University Medical Center Groningen, The 
Netherlands). In addition, we used one ATCC strain S. 
aureus ATCC 12600 (MIC gentamicin = 1 µg/mL) and one 
bioluminescent strain S. aureus Xen36 (MIC gentamicin 
= 0.75 µg/mL). The bioluminescent strain produces 
luciferase and its substrate constitutively, resulting in a 
photon-emitting state when metabolically active. This 
strain was obtained commercially from Perkin Elmer 
(Massachusetts, USA). The MIC of gentamicin for all 
strains was determined using the E-test (Biomerieux, 
MarcyI`Etoile, France).
 Staphylococci were cultured from cryopreservative 
beads (Protect Technical Service Consultants Ltd., United 
Kingdom) onto blood agar plates at 37 °C in ambient air 
for 24 h. For the preparation of experimental cultures, 
one colony was inoculated into a 10 mL batch culture 
of Tryptone Soya Broth (TSB: Oxoid, UK), cultured for 
18 h at 37 °C, and this overnight culture was diluted with 
TSB to an optical density (at 600 nm) of 0.1 which equals 
approximately 108 bacteria/mL.
Antibacterial efficacy of the PLGA-gentamicin-HA-
coating
Longevity of the antibacterial efficacy
To determine the 24 h bacterial growth inhibition of the 
coating and its longevity, staphylococcal cultures were 
used to inoculate TSA plates with a sterile cotton swab, 
according to methodological details described before (Neut 
et al., 2011). Ten minutes after inoculation, the PLGA-
gentamicin-HA-coated coupons were placed in the centre 
of each plate, with little or no additional pressure. Agar 
plates were incubated for 24 h at 37 °C in ambient air, after 
which the width of the inhibition zones for each sample 
were measured. The inhibition zone was calculated by 
subtracting the diameter of the coupon from the inhibition 
zone diameter and dividing the difference by two. The 
experiments were done in triplicate with separately grown 
bacterial cultures and on separate agar plates. Immediately 
following the first zone of inhibition measurement, coupons 
were transferred to a freshly inoculated agar plate every 
24 h to determine the longevity of the gentamicin release. 
This was repeated on a daily basis up to 4 days.
Bacterial killing in an interfacial gap
To determine the bacterial killing of PLGA-gentamicin-
HA-coating in a confined spacing, the 3M Petrifilm Aerobic 
Count (AC) medium system was used, as described before 
from a methodological perspective (Neut et al., 2011). 
A Petrifilm AC plate (3M Microbiology, St. Paul, USA) 
consists of two films, a bottom film containing standard 
nutrients, a cold-water gelling agent, and an indicator dye 
that facilitates colony counting, and a top film enclosing 
the sample within the Petrifilm system. The bottom film 
containing the gelling-agent can be inoculated with sterile 
demineralised water after which both films are pressed 
together and gelling occurs after 30 min. For the current 
experiments, 50 µL aliquots of bacteria suspended in 
fresh TSB to different concentrations between 103 and 
109 bacteria/mL, as determined in a Bürker-Türk counting 
chamber, was placed on top of a PLGA-gentamicin-
HA-coated coupon after which the Petrifilm was folded 
together. Petrifilm plates were incubated at 37 °C for 48 h 
and colony forming units (CFU) counts determined. On 
average, the bacterial suspension spread to a diameter of 
2.5 cm, implying a confined spacing with a thickness of 
100 µm. Multiplication of the suspension volume (50 µL) 
with the bacterial concentration yields the total bacterial 
challenge per coupon (4.9 cm2). All experiments were done 
in triplicate with separately prepared bacterial suspensions.
Bioluminescence imaging
Potential suitability of the PLGA-gentamicin-HA-coating 
for use in total hip replacement is further assessed by 
determining its ability to prevent bacterial growth in a 
biofilm assay. Longitudinal bacterial growth prevention of 
a gentamicin-coating in absence of HA was demonstrated 
using a recent geometrically-relevant model in which a 
gentamicin-coated miniature stem was mounted in an 
aqueous agar surrounding into which the gentamicin 
released could diffuse, as described in detail before (Neut 
et al., 2012). In short, the stem-holder allowed placement 
of a stem in its centre through a slot over half the depth 
of the bottom plate. The sterilised stem-holder was filled 
with liquid TSA with a sterile uncoated miniature stem in 
place. After cooling and solidification of the agar, the stem 
was removed, creating a perfect mould of the stem in the 
centre of the agar.
 A culture of bioluminescent S. aureus Xen36 in TSB 
was then diluted and suspended to a concentration of 
1 × 104 bacteria/ml in fresh TSB. These suspensions 
were used to contaminate the inside of the mould using a 
cotton swab. To this end, a sterile cotton swap was dipped 
3 times in the bacterial suspension and gently moved 
over the inner mould surface. This procedure yielded 
transfer of approximately 150 bacteria from the swab to 
the mould surface (Neut et al., 2012), corresponding with 
4 bacteria/cm2 mould surface. This represents a clinically 
realistic bacterial challenge based on available data on 
peri-operative contamination during a 1 h surgery in 
operating theatres with conventional ventilation systems 
(Sossai et al., 2011; Verkkala et al., 1998; Fitzgerald, 
1979). After 10 min of drying, a sterile HA-coated or 
PLGA-gentamicin-HA-coated miniature stem was inserted 
and the entire system was incubated for 60 h at 37 ºC in a 
bio-optical imaging system.
 Bioluminescence was imaged with a CCD camera 
(IVIS® Lumina II, Caliper Life Sciences, Hopkinton, MA, 
USA) directly following insertion of the stem on an hourly 
basis throughout the experimental period up to 60 h. A 
bioluminescent image was obtained with 5 min exposure 
time using 7.5 cm field of view and 5 cm sample height, 
binning of 4, 1/f stop and open filter. Bioluminescence 
imaging was performed with the top cover of the stem 
holder removed, thus focusing on the top of the agar and 
imaging bioluminescence along the length of the stem. 
As a region of interest (ROI), a circular shell was taken 
around the stem. To this end, two circular ROIs were first 
defined: one with a diameter coinciding with the diameter 
of the miniature stem and one with a larger diameter of 
3.0 cm around the centre (insert Fig. 4). Subsequently, 
the bioluminescences from both ROIs were subtracted 
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to yield the bioluminescence arising from the colonised 
zone around the stem. Bioluminescence was quantified as 
total bioluminescent flux (p/s) within the circular shell by 
using Living Image® 3.0 software (Xenogen, Alameda, 
CA, USA). The experiments were done in triplicate with 
separately cultured bacteria.
Animal experiments – infection prophylaxis model
Study design
The study was carried out in four groups with a total 
of 14 female New Zealand White albino rabbits. Two 
groups (HA- and PLGA-gentamicin-HA-coated pins) 
were sacrificed at day 2 post-operatively (3 animals/
group) and two similar groups were sacrificed at day 7 
post-operatively (4 animals/group). The group sizes were 
determined by the following power calculation: at day 2, 
we anticipated a mean CFU count of 6 log (SD = 3) in the 
HA-coated group and in the PLGA-gentamicin-HA-coated 
group ≤ 1 log (SD = 1). With an alpha level of 0.05 and a 
power of 80 %, sample size needed in each group was 3 
animals. At day 7, we anticipated a mean CFU count of 
7 log (SD = 4) in the HA-coated group and again ≤ 1 log 
(SD = 1) in the PLGA-gentamicin-HA-coated group. With 
an alpha level of 0.05 and a power of 80 %, sample size 
needed in each group was 4 animals.
 All experiments were carried out at a contract research 
facility (MPI Research, Mattawan, MI, USA). The study 
design was approved by MPI Research in compliance 
with all applicable regulations governing care and use of 
laboratory animals in the USA.
Surgical procedure
Surgery was carried out under aseptic conditions, after 
performing anaesthesia and starting pain management. 
Skin incision was made over the greater trochanter of the 
right limb and the gluteal muscles were retracted to allow 
access to the piriformis fossa. A hole with the final size of 
2.5 mm was created by inserting a 1.0 mm Kirschner wire 
(K-wire) into the femur/medullary canal and subsequently 
the hole was gradually enlarged, to prevent fracture of the 
cortical bone, by drilling over the K-wire with a 2.0 mm 
and a 2.5 mm drill bit. After the hole was created, the 
medullary canal was flushed with sterile saline to remove 
most of the marrow.
 The medullary canal was inoculated with gentamicin-
sensitive S. aureus ATCC 25923 (MIC gentamicin = 1 µg/
mL) (Hess et al., 2011) using a micropipette. Each animal 
received 100 µL of a bacterial suspension (1 × 106 CFU/
mL) to a final dose of 1 × 105 CFU per site. This inoculation 
dose was chosen due to results of a pilot study, showing 
induction of infection without causing death of the animals. 
An HA- or PLGA-gentamicin-HA-coated pin was inserted 
into the canal using an insertion tool to avoid direct 
handling of the implant surface. Once the pin was placed, 
the defect opening was filled with bone wax, muscle and 
subcutaneous layers were sutured in a routine fashion, and 
the skin was closed with skin glue.
 The animals were euthanised at day 2 or 7 and the right 
femur was harvested under sterile conditions. Macroscopic 
observations of the implant sites (e.g. abscess formation 
or cortical lysis) were recorded. The distal third of the 
femur was removed using surgical rongeurs and the pin 
was explanted from the medullary canal. The distal and 
proximal femur segments and the pin itself were collected 
in separate sterile containers.
Microbiological evaluation
Samples of bone adjacent to the pins were weighed on 
receipt and placed in 50 mL tubes. If the samples weighted 
over 2 g, they were cut up using sterile instruments. Five 
mL of sterile saline per g bone was added to each tube 
and bone samples were homogenised for 1 min using a 
Polytron homogeniser PT 1200 E (Kinematica AG). The 
pins were transferred to a sterile 15 mL tube and 5.5 mL of 
TSB medium was added to each tube. Pins were sonicated 
for 7 min at 40 kHz and 150 W using a Crest Ultrasonics 
Sonicator and then vortexed for 3 min. All samples were 
kept on ice water in order to avoid bacterial growth.
 Standard 96-well microdilution plates (Costar 3795; 
Fisher Scientific, Pittsburgh, US) were filled with 270 µL 
sterile saline or TSB medium, except for column 1. Three 
hundred µL of sample was loaded into column 1 and the 
samples were serially diluted 10-fold across the plate. From 
columns 1-8 (undiluted sample through the 10-7 dilution), 
10 µL aliquots were spotted in duplicate across the top of 
a square agar plate. The agar plates were then tilted at a 
45-90° angle to allow the 10 µL aliquot to track across the 
agar surface to the opposite side of the plate. The plates 
were laid flat, allowed to dry at room temperature, inverted, 
and incubated at 35 ºC for 24-48 h. Colonies were manually 
counted and counts were converted to log-units CFU per 
gram bone or per pin.
Haematological evaluation
Haematological evaluations were conducted pre-operatively 
for all animals, on days 1 and 2 post-operatively for animals 
in the day-2 sacrifice groups, and on days 4 and 7 post-
operatively for the animals in the day-7 sacrifice groups. 
Blood samples were taken from the jugular vein. Samples 
were placed in tubes containing ethylenediaminetetraacetic 
acid for evaluation of haematology parameters (leukocyte 
count -total and absolute differential-, erythrocyte count, 
haemoglobin, haematocrit, absolute reticulocytes, platelet 
count, and blood cell morphology) using an automated 
haematological analyser ABX Micros ES 60 (HORIBA 
Medical, Kyoto, Japan).
Animal experiments – bone ingrowth model
Study design
The study was carried out in four groups with a total of 12 
male Beagles at a contract research facility (MPI Research, 
Mattawan, MI, USA). The study design was approved by 
MPI Research in compliance with all applicable regulations 
governing care and use of laboratory animals in the USA. 
Beagles were selected because of their wide-spread use for 
evaluating implants in bone (Turner, 2001). Additionally, 
the Beagle distal femoral condyle is sufficiently large 
to hold two implants per knee, reducing the number of 
animals required for the study. Two groups (HA- and 
PLGA-gentamicin-HA-coated pins) were sacrificed at 
week 4 post-operatively (5 animals), and two similar groups 
were sacrificed at week 12 post-operatively (7 animals). 
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The group sizes were determined by the following power 
calculation: at week 4, we anticipated a mean bone-implant 
contact of 40 % (SD = 6 %) in the HA-coated group and 
30 % (SD = 5 %) in the PLGA-gentamicin-HA-coated 
group. With an alpha level of 0.05 and a power of 80 %, 
sample size needed in each group was 5 animals. At week 
12, we anticipated a mean bone-implant contact of 60 % 
(SD = 7 %) in the HA-coated group and 50 % (SD = 6 %) 
in the PLGA-gentamicin-HA-coated group. With an alpha 
level of 0.05 and a power of 80 %, sample size needed in 
each group was 7 animals.
 The 4-week period is regarded as the time required for 
initial bone ingrowth and fixation of the pin, while the time 
point of 12 weeks was added as further data on medium-
term bone integration (Alt et al., 2011; Bobyn et al., 2009; 
Moojen et al., 2009).
Surgical procedure
After induction of anaesthesia, each animal was placed on 
its side on the surgical table and a skin incision was made 
over the distal femur. The skin was retracted and the muscle 
and soft tissue over the femur were reflected to expose 
the lateral condyle. Two circular defects, approximately 
4.8 to 5.4 mm in diameter, were placed 12 to 17 mm apart 
(from centre of defect to centre of defect) parallel to the 
distal femur condylar plateau. Each defect was drilled 
perpendicular to the lateral condyle surface, through the 
cortex, until the medullary cavity was breached. The first 
defect was created in the approximate centre of the lateral 
condyle and the second defect positioned relative to the 
first.
 All pins were handled using a specifically designed 
insertion tool and they were placed so that the pin was 
surrounded by cancellous bone and not in contact with the 
opposing cortical bone. Once each pin had been placed, the 
drilled bone defect was filled with bone wax, the muscle 
and subcutaneous layers were sutured in a routine fashion, 
and the skin was closed with skin glue. The animal was 
repositioned on its opposite side and the procedure was 
repeated on the contralateral femur.
 At the end of the 4 and 12 week recovery periods, the 
animals were euthanised by an intravenous overdose of 
sodium pentobarbital solution followed by exsanguination 
by severing of the femoral or axillary vessels. The left and 
right distal femora were removed.
Biomechanical testing
Each condyle was potted in dental cement making sure the 
cement did not come into contact with the pin directly or 
through the cancellous bone bed. The potted specimen was 
mounted directly under the pull-out grip and positioned 
so that the axis of the pin was aligned in parallel with 
the direction of the pull-out force. The pull-out grip was 
centred over the specimen and raised at a rate of 1 mm/
min. Ultimate pull-out force was recorded for each pin and 
fixation strength was calculated (pull-out force / surface 
area of the pin).
Histomorphometry
Pins for histomorphometry were excised leaving a 
sufficient bone collar (5 mm minimum) around the pin, 
placed in 10 % neutral buffered formalin, and shipped 
for histology slide preparation. Histology samples were 
embedded in an acrylic resin (Technovit 7200), sectioned 
and stained with Sanderson’s Rapid Bone Stain. Digital 
photos of the slides were taken and image analysis was 
carried out using the colour recognition software in 
BioQuant. The bone-pin contact was measured and the 
scores were reported as a percentage of the pin surface area. 
Region of Interest encompassed the contact area along the 
full length of the interface between the bone defect surface 
and the pin surface.
Statistical analysis
Influence of the gentamicin-releasing coating on bacterial 
growth around the miniature stems was determined 
through comparison of the integrated photon flux around 
miniature stems with HA- or PLGA-gentamicin-HA-
coatings using the unpaired Student’s t-test, accepting 
p ≤ 0.05 as statistically significant. Likewise, for the 
animal experiments the influence of the PLGA-gentamicin-
HA-coated pins on bone fixation, osseointegration, and 
infection resistance was determined through comparison of 
the fixation strength, percentage of bone-implant contact, 
and bacterial and neutrophil count in the animals groups 
with an HA-coated pin using the unpaired Student’s t-test, 
accepting p ≤ 0.05 as statistically significant.
Results
Gentamicin release
PLGA-gentamicin-HA-coatings demonstrate an initial 
burst release of around 95 % of the gentamicin incorporated 
within the first 1-2 h, followed by slow release of an 
additional 2 % up to 6 h. After about 168 h, 100 % of the 
gentamicin was released from the PLGA-gentamicin-HA-
coating (Fig. 2). SEM micrographs (Fig. 1) indicate that 
the PLGA-overlayer had disappeared within 336 h, leaving 
the surface structure of the HA-coating intact.
Antibacterial efficacy
All staphylococcal strains, including gentamicin-resistant 
S. epidermidis 7388 and S. epidermidis 7391 are inhibited 
in their growth on agar during the first 24 h of gentamicin 
release from the coating (Fig. 3). The growth inhibition 
observed towards resistant strains can be attributed to the 
high initial burst release of the gentamicin from the coating. 
The antibacterial efficacy of the PLGA-gentamicin-HA-
coating gradually decreases with time. Antibacterial 
efficacy disappears most readily for the gentamicin-
resistant strains while some residual antibacterial activity 
is seen for the most sensitive strains after 96 h (Fig. 3). 
No zones of inhibition were observed around HA-coated 
coupons without gentamicin.
Bacterial killing in interfacial gap model
At a bacterial challenge of 10 bacteria/cm2 substratum 
surface, HA-coated coupons allowed growth of around 
27 CFUs per coupon in the confined spacing between 
coupons and the Petrifilm, regardless of the staphylococcal 
strain involved, whereas no CFUs or in a few occasions 
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1 or 2 CFUs, were seen in the confined space between 
PLGA-gentamicin-HA-coated coupons and the Petrifilm 
until a bacterial challenge of 107 bacteria/cm2 was reached. 
Note that at a challenge of 107 bacteria/cm2, representing 
a clinically unlikely high total challenge, no CFUs were 
seen, not even for the gentamicin-resistant strains included.
Longitudinal antibacterial efficacy in geometrically-
relevant model
Our data indicate that the gentamicin-susceptibility of 
bioluminescent S. aureus Xen36 is within the range of the 
other staphylococcal strains used (Fig. 3).
 Photon fluxes arising from bioluminescent S. aureus 
Xen36 colonising the miniature stem and its surrounding 
become measurable after 30-40 h of growth around 
HA-coated stems (Fig. 4) and increase more than two 
log-units with time up to 60 h (statistically significant 
at p = 0.005) after which the agar started to dry out, in 
a fashion resembling a normal bacterial growth curve. 
No measurable photon fluxes arise from colonising 
staphylococci when a PLGA-gentamicin-HA-coated stem 
is inserted in bacterially contaminated agar, indicating the 
antibacterial efficacy of the coating.
Fig. 2. The cumulative 
gentamicin release (µg/
cm 2)  as  a  funct ion of 
time after release from 
gentamicin-HA-coated 
coupons with a protective 
PLGA-overlayer. Error bars 
denote the average standard 
deviation over three separate 
experiments performed 
per time point.  Insert: 
Cumulative gentamicin 
release expressed as a 
percentage of the total 
amount  of  gentamicin 
incorporated.
Fig. 3. Width of the zones of inhibition (mm) around gentamicin-HA-coated titanium coupons with a protective PLGA-
overlayer on TSA plates as a function of time for six different staphylococcal strains. Growth inhibition zones were 
measured 24 h after inoculation, after which coupons were transferred to a freshly inoculated agar plate and incubated 
for another 24 h. This procedure was repeated every 24 h to determine the longevity of the antibiotic release up to 4 
days. Data represent averages over three separate experiments with error bars indicating the standard deviation. For 
each strain, significant differences (p < 0.05) within a time series with respect to the day before is indicated by *.
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Animal experiments – infection prophylaxis model
HA- and PLGA-gentamicin-HA-coated pins were inserted 
in bacterially contaminated medullary canals in rabbits, 
defining ‘‘infection’’ as staphylococcal presence at the 
bone-implant interface, i.e. colonisation of the pin surface 
and in surrounding tissue. Accordingly, infection rates 
were 100 % (7 out of 7 animals) for the rabbits with HA-
coated pins and 0 % (0 out of 7 animals) for the rabbits 
with PLGA-gentamicin-HA-coated pins. High levels of 
staphylococci were recovered from the femora of rabbits 
implanted with an HA-coated pin, while all rabbits 
implanted with a PLGA-gentamicin-HA-coated pin failed 
to produce bacterial colonies from either the femur or 
pin samples (Fig. 5a), yielding a statistically significant 
reduction (p = 0.001).
 The infected animals did not show any signs of 
systemic septic disease during the entire observation 
period. Furthermore, body temperatures recorded during 
the study were comparable to pre-operative values for both 
groups. Noteworthy clinical findings (dehiscence or/and 
erythema) were limited to some animals implanted with an 
HA-coated pin. Mean body weight loss was slightly larger 
(not statistically significant) for animals implanted with the 
HA-coated pin (10 % weight loss) compared to animals 
with a PLGA-gentamicin-HA-coated pin (5 % weight 
loss). Haematological analyses in animals implanted with 
HA-coated or PLGA-gentamicin-HA-coated pins showed 
a significant reduction in neutrophil (p = 0.003; Fig. 5b), 
basophil (p = 0.035; Fig. 5c), and monocyte (p = 0.027; 
Fig. 5d) counts for the PLGA-gentamicin-HA group after 
implantation compared to the HA group. Accordingly 
total leukocyte counts were significantly (p = 0.023) 
higher in animals implanted with HA-coated (9.85 × 103/
µL) than in animals with PLGA-gentamicin-HA-coated 
pins (6.85 × 103/µL). In addition, platelet counts in 
animals implanted with PLGA-gentamicin-HA-coated 
pins showed a significant reduction (p = 0.002; Fig. 
5e) after implantation compared to the HA group. No 
significant differences were observed between both groups 
in eosinophil, lymphocyte, erythrocyte, and absolute 
reticulocyte counts, and in haemoglobin and haematocrit 
values.
Animal experiments – bone ingrowth model
Noteworthy clinical findings were observed in two animals, 
but resolved prior to euthanisation. During week 2 and 3, 
one animal had impaired hind limb function on the right 
side, which was implanted with PLGA-gentamicin-HA-
coated pins, while another animal (implanted with HA-
coated pins) had swelling on the left hind limb at week 
3. Incidentally, the average amount of PLGA on two pins 
decreased with 61 % and 96 % after 1 and 4 weeks, as 
Fig. 4. Bioluminescence imaging of staphylococcal growth around miniature stems. Photon fluxes arising from a 
circular shell around miniature stems mounted in an agar mould contaminated with bioluminescent S. aureus Xen36 
for HA-coated and PLGA-gentamicin-HA-coated stems as a function of time. All experiments were done in triplicate 
and data represent averages ± SDs. Insert: top-view of the bioluminescence signal around a miniature stem with (left) 
and without (right) a PLGA-gentamicin-releasing coating (indicated by the smallest red circle) in an agar mould, 
contaminated with bioluminescent S. aureus Xen36 after 31 h of incubation at 37 °C. Bioluminescence is displayed 
on a pseudo-colour scale, high numbers of photons per second (p/s) appear red, while low numbers appear blue. The 
circular shell in between the red circles indicates the ROI for quantitative analysis of the bioluminescence.
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Fig. 5. Infection prevention with PLGA-gentamicin-HA-coated pins in a rabbit model. (A) Number of staphylococci 
recovered from femora and the pin itself at day 2 and 7 after insertion of HA-coated or PLGA-gentamicin-HA-coated 
pins in the medullary canal of rabbits. The medullary canal was contaminated with 1 × 105 CFU of S. aureus ATCC 
25923 prior to insertion of the pin. *denotes statistical significance at p < 0.05 between PLGA-gentamicin-HA-coated 
and HA-coated. (B) Neutrophil counts (cells/mm3) for HA-coated and PLGA-gentamicin-HA-coated pins in the 
medullary canal of rabbits. The medullary canal was contaminated with 1 × 105 CFU/site of S. aureus ATCC 25923 
prior to insertion of the pin. Haematological evaluations were done pre-operative and 1, 2, 4 and 7 days post-operatively. 
Data represent mean ± standard deviations. *denotes statistical significance at p < 0.05 between PLGA-gentamicin-
HA-coated and HA-coated. (C) As in Fig. 5b, for basophil counts. (D) As in Fig. 5b, for monocyte counts. (E) As in 
Fig 5b, for platelet counts.
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determined by Cordis Corporation/Conor Medsystems, 
LLC, Fremont, US). No PLGA was detected on explanted 
pins after 12 weeks.
 At 4 weeks, PLGA-gentamicin-HA-coated pins had 
lower fixation strength than HA-coated pins (Fig. 6a; 
p = 0.184). Nevertheless, the mechanical strength of the 
interface after 12 weeks was higher (p = 0.094) for the 
PLGA-gentamicin-HA-coated pins (Fig. 6a), ensuring 
better bone fixation in time.
 Image analysis showed that mean overall percentages 
of bone-implant contact after 4 weeks were 40.0 % for the 
HA-coated pins and 31.8 % for the PLGA-gentamicin-
HA-coated pins (Fig. 6b; p = 0.0001). After 12 weeks, 
HA-coated pins still showed slightly higher percentages 
of bone-implant contact (Fig. 6b), but this difference did 
not reach statistical significance (p = 0.365).
Discussion
The peri-prosthetic region in total joint arthroplasties is 
highly sensitive for bacterial biofilm formation (Campoccia 
et al., 2006). Fast tissue integration of HA-coatings is 
considered to reduce the risk of biofilm formation after 
peri-operative bacterial contamination of the implant 
and its surrounding (Geesink et al., 1987; Søballe et al., 
1990; Dhert et al., 1993). However, Vogely et al. showed 
in a rabbit infection model that HA-coated implants had 
a higher infection susceptibility compared to uncoated 
titanium implants (Vogely et al., 2000) which negates the 
advantage of better bone integration and implant fixation 
(Oosterbos et al., 2002) and underscores the need for 
infection prophylaxis in cementless applications. Currently, 
there are no strategies available for local antibiotic delivery 
from cementless prostheses. HA is mostly applied to 
prosthetic surfaces by plasma spraying and the high 
processing temperatures associated with plasma spraying 
make incorporation of antibiotics impossible (Stigter et 
al., 2002). Incorporation of antibiotics in HA-coatings 
on titanium prostheses has been established using a 
‘‘biomimetic’’ coating technology at 37 ºC with deposition 
of amorphous calcium phosphate on titanium followed by 
immersion of the prostheses in a supersaturated calcium 
phosphate solution containing the antibiotics (Stigter et 
al., 2004). However, the dose of antibiotics that could be 
Fig. 6. Bone fixation and osseointegration with PLGA-
gentamicin-HA-coated pins in a canine condylar defect 
model. Data represent mean ± standard deviations and 
*denotes statistical significance at p < 0.05 between 
PLGA-gentamicin-HA-coated and HA-coated. (a) 
Fixation strength (N/mm2) for HA-coated and PLGA-
gentamicin-HA-coated pins in the distal femoral 
condyle of beagles. Pull-out testing was done 4 and 
12 weeks post-operatively. (b) Osseointegration, 
expressed by amount of bone-implant contact at week 
4 and 12 after insertion of HA-coated or PLGA-
gentamicin-HA-coated pins in the distal femoral 
condyle of beagles. Results are reported as a percentage 
of the implant surface area.
Table 1. A comparison of the pre- and post-exposure 
antibacterial efficacy of gentamicin-HA-coatings in 
absence and presence of a protective PLGA-overlayer 
against gentamicin-resistant S. epidermidis 7388, obtained 
prior to and after exposure of samples for 2 h in sterile 
PBS at 37 °C. Data represent averages over three separate 
experiments with ± indicating the standard deviation.
Pre-exposure efficacy
Coating Number of CFU per coupon
HA-coated 28 ± 3 a
PLGA-gentamicin-
HA-coated 0 ± 0 
b
Post-exposure efficacy
Gentamic in -HA-coa ted 
(no PLGA-overlayer) 21 ± 14 
c
PLGA-gentamicin-
HA-coated 9 ± 9 
a,b,c
a significantly different at p = 0.026
b no significant difference at p = 0.158
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incorporated this way is very limited and about 300 times 
lower than the gentamicin dose applied in our current 
PLGA-gentamicin-HA-coating, making this an unsuitable 
way for effective prophylaxis. Moreover, these coatings 
suffer from a rapid wash-out by body fluids (Radin et 
al., 1997): almost 100 % of incorporated gentamicin was 
released within 1 h (Stigter et al., 2004). The coating 
investigated here protects the antibiotic sprayed onto 
the HA-coating through a PLGA-overlayer to yield 
an antibacterially effective release of gentamicin over 
clinically relevant time scales of up to 4 days, which is 
in fact longer than currently achieved using pre-operative 
antibiotics, usually given as a single dose 60 min before 
the surgical procedure (Bratzler et al., 2013). Although the 
feature of burst release within the first hours of exposure 
of the coating to a fluid may seem disappointing, this 
high burst release is important in order to kill bacteria 
introduced during the surgery (Knobben et al., 2006). At 
the same time, gentamicin release is fully confined to about 
7 days which presents a clear advantage over the use of 
antibiotic-loaded bone cements in cemented applications, 
demonstrating a relatively low concentration tail-release 
of antibiotics, thereby limiting the risk of development of 
antibiotic-resistant strains (Thomes et al., 2002).
 One of the critically important considerations 
when evaluating new antimicrobial technologies is the 
selection of appropriate and relevant in vitro models. The 
antibacterial efficacy of our PLGA-gentamicin-HA-coating 
was evaluated in three different in vitro systems and in an 
in vivo animal model. While zones of inhibition are well-
accepted and effective for comparing antibacterial efficacies 
of an antibiotic, they are not necessarily representative of 
the clinical situation. In orthopaedic prostheses, the clinical 
situation is characterised by both close proximity between 
the prosthesis and the bone surface, and limited fluid 
volumes and flow. Therefore, we studied staphylococcal 
survival in a confined space using a Petrifilm assay, as 
previously developed and published (Neut et al., 2011). 
Appropriate and clinically relevant in vitro systems and 
in vivo animal models are especially important in the 
evaluation of coatings in orthopaedics intended to reduce 
infection rates, because clinical studies in humans to 
demonstrate statistically significant reductions in infection 
rates are practically impossible due to the high number of 
patients required for such studies. In the hypothetical case, 
where the efficacy of a coating in reducing the incidence of 
infection has to be demonstrated in a clinical trial, a simple 
power calculation shows that studies aiming to demonstrate 
a 50 % reduction – in an existing infection incidence of 
2 % at a conservative statistical significance of p < 0.05 – 
requires the inclusion of around 5,000 patients, who must 
be followed longitudinally over several years (Darouiche 
et al., 1999). Such statistical considerations place a heavy 
burden on the selection of proper in vitro and in vivo animal 
experiments, although demonstration of the incidence of 
infection, as opposed to a reduction in biofilm formation, 
also requires large animal cohorts. All three in vitro systems 
applied here demonstrate antibacterial efficacy of our 
PLGA-gentamicin-HA-coatings, most notably so against 
gentamicin-resistant strains at very high bacterial challenge 
concentrations of up to 1 × 107 bacteria/cm2. Importantly, 
these in vitro results are confirmed in an animal experiment. 
The animal study had a limited, but sufficient power to 
yield statistically significant conclusions and support the 
findings of our in vitro methods, as currently the use of 
large numbers of animals in vivo is becoming increasingly 
troublesome (Richmond, 2002).
 Although there are several published studies that 
investigate the in vivo efficacy of antibiotic releasing 
coatings for the prevention of infection (Giavaresi et al., 
2014), relatively fewer studies employ HA-coatings to 
do so. Alt et al. (2006) reported on the efficacy of two 
different gentamicin-HA-coatings on steel K-wires in the 
prevention of infection. They showed good results, as 
infection rates decreased from 88 % for HA-coated K-wires 
to 0 % for both types of gentamicin-HA-coated K-wires. 
More recently, Moojen et al. (2009) investigated the 
efficacy of tobramycin-HA coated implants in preventing 
infection. For a S. aureus challenge in a rabbit model 
6 % of the tobramycin-HA-coated titanium foam rods 
were infected after 28 days, compared to 53 % and 67 % 
for the HA-coated titanium and uncoated titanium rods, 
respectively. Both studies, however, have no protective 
PLGA-overlayer, unlike our current PLGA-gentamicin-
HA-coating. This thin biodegradable overlayer serves to 
protect the gentamicin layer during transit and surgical 
implantation, even when the prosthesis is hammered into 
a tight bone junction and the coating becomes disrupted, 
gentamicin release will occur at the implant-bone 
junction. The protective effects of the PLGA-overlayer 
are demonstrated in Table 1, showing antibacterial efficacy 
of the coatings after 2 h of exposure to a fluid (PBS 
in the present example). The PLGA-overlayer clearly 
slows down the release of gentamicin due to a longer 
diffusion trajectory, which is of clinical importance when 
the prosthesis might become in contact with body fluids 
prior to final insertion in the bone. The gentamicin-coated 
tibial nail that has been recently approved for clinical 
application in Europe and Canada, is equipped with a 
poly-DL-lactide (PDLLA)-layer in which gentamicin is 
dispersed (Schmidmaier et al., 2006), but its degradation 
is considerably slower than of our coating through the 
use of higher-molecular weight PDLLA (30 kDa versus 
17 kDa in our coating). This makes the gentamicin tibial 
nail with PDLLA-layer well suited for its application in 
trauma, where high antibiotic levels are needed during 
longer periods than in our application, which is aimed to 
prevent the development of infection due to peri-operative 
bacterial contamination of an implant and its surrounding 
tissue.
 The prophylactic gentamicin-HA-coating with a 
protective PLGA-overlayer developed here has the 
ability to resist local infection; all animals in the PLGA-
gentamicin-HA-coated group were free of infection 
despite an inoculation dose of 105 CFU/site of S. aureus. 
Infiltration of granulocytes is one of the first steps of 
an inflammatory process and generally encompasses 
neutrophils but also, to a much smaller, extent basophils 
(Schutte et al., 2009). Yet, significant reductions in both 
neutrophil and basophil counts in animals implanted with 
PLGA-gentamicin-HA-coated pins were noticed. As 
neutrophils are the primary white blood cells that respond 
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to invading S. aureus in order to bind and ingest them 
(Rigby and DeLeo, 2012), this is an important finding. 
It is widely recognised that bacteria causing prosthetic 
hip infections grow in biofilms. Therefore, any antibiotic 
coating for cementless hip prostheses should be capable 
of preventing bacterial biofilm formation. Our animal 
model showed complete bacterial growth inhibition on 
all PLGA-gentamicin-HA pins implanted, both 2 and 7 
days after placement. It seems presumable that “sealing” 
the gentamicin-HA-coating with a PLGA-overlayer bears 
the risk of impairing bone ingrowth, which determines the 
long-term survival of cementless prostheses in total joint 
replacements. However, 12 weeks after implantation, 
PLGA-gentamicin-HA-coated pins performed slightly 
better in a pull-out test than did HA-coated pins and this 
effect on bone fixation strength of a gentamicin coating 
has been noticed before (Fassbender et al., 2013). Neither 
mechanically nor histomorphometrically were there any 
statistically significant differences, suggesting that our 
biodegradable PLGA-gentamicin-HA-coating does not 
impair long-term bone ingrowth.
Conclusions
The gentamicin-HA-coating with a protective PLGA-
overlayer shows good antibacterial efficacy in vitro, 
killing even gentamicin-resistant staphylococcal strains 
in the confined space of a simulated interfacial gap, 
as initially existing between a cementless prosthesis 
and cancellous bone. Moreover, we were able to 
longitudinally demonstrate the absence of bacterial 
growth of contaminating staphylococci along the PLGA-
gentamicin-HA-coated stems for at least 60 h. These in 
vitro results were all in line with results obtained in a 
rabbit model, demonstrating infection prophylaxis for 
at least 7 days, while not impairing bone fixation and 
osseointegration 12 weeks after implantation in a non-
rodent model. Our biodegradable PLGA-gentamicin-
HA-coating is a so-called combination device: clinically 
approved components (HA, a drug and a biodegradable 
polymer overlayer) are combined into a single platform. 
Combination devices are offered a unique regulatory review 
process to facilitate translation to clinical application (Wu 
and Grainger, 2006), although they still undergo lengthy 
approval processes that include in vitro testing, animal 
studies and clinical trials. Importantly, and in line with 
what is needed for the approval of a new drug (Web ref. 4), 
animal studies have been carried out in rodent-like and non-
rodent species. Inclusion of a non-rodent species is required 
in the safety assessment of pharmaceuticals to limit the 
uncertainty in the extrapolation process from animal 
toxicity data to the human situation (Web ref. 5). Based 
on these corroborative results, our PLGA-gentamicin-HA-
coating has a high potential, as an extremely appreciated 
clinical option for infection prophylaxis in cementless 
total joint replacement. Regulatory agencies, especially 
in the USA have been critical toward antibiotic-releasing 
coatings, fearing that long-term tail release of the antibiotic, 
as from gentamicin-loaded bone cements, stimulates 
the development of resistance among bacterial strains. 
Importantly, we demonstrate that the current coating 
effectively overcomes this critique, as antibiotic release 
is completed after dissolution of the PLGA-overcoat. 
Moreover, inclusion of other antibiotics in the coating will 
not affect the release mechanism.
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Reviewer III: If the polymer coating allows most fractional 
drug release within a few hours, why use PLGA at all? Why 
not use a slowly soluble calcium phosphate coating?
Authors: The thin PLGA-overlayer serves as a 
biodegradable layer to protect the gentamicin layer during 
transit and surgical implantation and not a priori to control 
antibiotic release. A calcium-phosphate coating was not 
used because calcium-phosphate is not strong enough 
during surgical implantation.
Reviewer III: What antibiotic dosing requirements are 
considered for this possible clinical application?
Authors: The gentamicin surface concentration was 
chosen, because its antibacterial efficacy matches with the 
antibacterial efficacy of gentamicin-loaded bone cement 
(Neut et al., 2011, text reference).
Reviewer III: Is local cell toxicity from rapid drug dose 
dumping an issue for these closed compartment models?
Authors: Our Beagle dog study shows (Figure 6) that the 
local gentamicin application does not negatively interfere 
with the long-term healing process, but even shows a small 
stimulation of the fixation strength. Furthermore, in vitro 
studies with osteosarcoma cells did not show any cytotoxic 
effects of the coating (Web ref. 3, text reference).
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Reviewer III: The future of gentamicin releasing 
technologies may be influenced by increasing gentamicin 
resistance amongst staphylococci. This is known to be 
a problem in gentamicin releasing bone cements, as the 
authors are well aware. How do the authors see this issue 
in terms of the performance of the described gentamicin 
releasing technology?
Authors: We are indeed aware of the increasing gentamicin 
resistance in staphylococci causing prosthetic joint 
infections. We chose gentamicin because of its wide-
spread clinical use, but our coating may as well be used 
in combination with other antibiotics.
Reviewer V: Insertion of an artificial joint is a vigorous act 
using a hammer forcing the implant in a press-fit fixation 
in a pre-reamed bone bed. Is the coating strong enough 
to withstand these forces? What would be the effect if 
the coating is disrupted in parts? Will the implant than be 
contaminated only on these specific points or will the burst 
release of gentamicin kind of cover these areas?
Authors: We have not performed any stability testing of 
the coating. However, since this is a release coating and 
not a (mono-) molecular coating, hammer blows may 
disrupt the integrity of the coating, but this will yield an 
increased burst-release utmost, since the antibiotic is in all 
cases made locally available.
Reviewer V: Around ⅔ of blood loss in THR occur after 
surgery has finished with blood flowing from the medullary 
canal along the implant to the joint. How much wash out of 
antibiotics will be possible without dropping the antibiotic 
concentration below the MIC?
Authors: When the released antibiotic falls below the 
MIC levels in vivo cannot be answered in any in vitro 
study. The answer critically depends on the volume used 
to release the antibiotics in and the turn-over of the fluid 
in that volume. Gentamicin is highly hydrophilic and 
spontaneous release will occur when left unprotected on a 
surface. The protective effect of the PLGA- overlayer in a 
moist environment clearly follows from the data in Table 1.
